SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in VolitionRx Ltd
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have reported a combined beneficial ownership of 9.99% of VolitionRx Ltd.'s common stock as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd are the reporting persons for this Schedule 13G Amendment No. 1.
- The filing pertains to their beneficial ownership of Common Stock, par value $0.001 per share, of VOLITIONRX LTD.
- As of December 31, 2024, the reporting persons collectively beneficially owned 9,343,265 shares of VolitionRx Ltd.'s common stock.
- This ownership represents 9.99% of the total class of securities.
- Armistice Capital, LLC, as an investment adviser, exercises shared voting and dispositive power over these shares through its management of Armistice Capital Master Fund Ltd., the direct holder.
- Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects.
Positives
- Disclosure of a significant institutional stake (9.99%) by Armistice Capital, LLC and Steven Boyd in VolitionRx Ltd, indicating a notable investment position.
Negatives
- The document does not contain any negative information regarding VolitionRx Ltd's operations or financial performance.
Risks
- The document does not identify specific risks related to VolitionRx Ltd's business or operations.
Future Outlook
The document is a beneficial ownership report and does not provide any forward-looking statements or guidance regarding VolitionRx Ltd's future performance or outlook.
Industry Context
This filing is a routine disclosure of a significant institutional ownership stake in a publicly traded company, common for investment funds and their principals. It does not provide broader industry trend analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership in the company.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event requiring the filing of this statement (snapshot of ownership). |
| 02/14/2025 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
VolitionRx Ltd, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.